- Data around recently launched Clareon® IOL material
showcases excellent vision and lasting clarity—three years after
implantation1
- ARGOS® Biometer with Image Guidance demonstrates significant
time savings for cataract surgery planning2-4
- Additional real-world data on Alcon’s surgical portfolio
along with interactive, educational events will be showcased at the
meeting
Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated
to helping people see brilliantly, will once again have a
significant scientific presence at the American Society of Cataract
and Refractive Surgery (ASCRS) 2022 Annual Meeting, taking place
April 22-26 in Washington, D.C. Approximately 150 abstracts feature
Alcon’s leading ophthalmic products and equipment—with more than 60
sponsored by Alcon—reinforcing the company’s continued commitment
to research and innovation. Registration links for events taking
place onsite and booth information is available at
MyAlconatASCRS.com.
“Alcon is proud to have yet again the largest scientific
presence in ophthalmic surgical devices at the ASCRS meeting,” said
Sergio Duplan, President, North America at Alcon. “The innovation
and data presented at this year’s event demonstrates that our
products and services continue to support surgeons in delivering
the practice efficiencies and brilliant outcomes that they have
come to expect.”
Data demonstrates excellent vision, predictable refractive
outcomes and glistening-free* clarity with Clareon®, Alcon’s
most advanced intraocular lens (IOL) material.1,5
A study from Nuijts et al. demonstrates that Clareon delivers
excellent visual outcomes and remained glistenings-free* three
years after implantation.**,1 Study findings based on the
multinational patient trial for those implanted with Clareon
resulted in adverse event data consistent with its known safety
profile and zero unanticipated adverse events.1 Additionally, 96.7%
of patients did not develop posterior capsule opacification (PCO)
requiring Nd YAG capsulotomy, or a secondary cataract, at three
years.1
Additional Alcon-sponsored presentations showcasing Clareon
results and key findings include:
- Evaluation of Binocular Visual Acuity and Refractive Stability
in a Novel Monofocal Hydrophobic Intraocular Lens, Presented by Dr.
Clayton G. Blehm (April 23, 4:15-4:20 p.m.)
- Head-to-Head Comparison of Intermediate Vision of Two Monofocal
Intraocular Lenses, Presented by Dr. J. Morgan Micheletti (April
23, 3:45-3:50 p.m.)
Studies on time savings and prediction error for cataract
surgery with the ARGOS® Biometer, the fastest-growing† Swept
Source Optical Coherence Tomography (SS-OCT) biometer equipped with
Image Guidance for a faster and smarter planning
solution.**,2-4
Results from a real-world study highlight that ARGOS delivers
significant time efficiencies for dense and non-dense patients in
cataract evaluation.**,2 The ARGOS patients had a 0% acquisition
failure rate, which was superior to the other biometers in the
study, reducing the need for Manual A-scan.2 Other Alcon-sponsored
studies on ARGOS will be presented, including:
- Comparison of Toric Calculations From Two Swept-Source Optical
Coherence Tomography Devices, Presented by Dr. Robert F. Melendez
(April 22, 10:00-10:05 a.m.)
- Refractive Outcomes Comparison of a Swept-Source Optical
Coherence Tomography Biometer and an Optical Low Coherence
Reflectometry Biometer, Presented by Dr. Clayton G. Blehm (April
23, 9:11-9:16 a.m.)
More than 30 Alcon-sponsored studies on Alcon’s leading
presbyopia-mitigating IOLs, showing consistent positive
outcomes as well as high patient satisfaction.6-10
Notably, a large-scale, real-world assessment of Vivity® data
will be presented. “Real World Visual Performance and Patient
Satisfaction outcomes of a novel wavefront-shaping Presbyopia
Correcting IOL in Cataract patients,” from Lapid-Gortzak et al.
showcases that patients implanted with the lens continued to
demonstrate good distance, intermediate and functional near visual
outcomes, as well as high patient satisfaction and low levels of
visual disturbances.**,6
Additional Vivity and PanOptix® data from Alcon-sponsored
studies will be presented, including: 8,9
- A Cost Benefit Analysis of New Extended Depth of Focus
Presbyopia Correcting Intraocular Lens from US Patient Perspective,
Presented by Dr. Cathleen M. McCabe (April 25, 10:00-10:05
a.m.)
- Comparison Between Two Diffractive Presbyopia Correcting
Implants That Provide Continuous Range of Vision: A Randomized
Bilateral Study, Presented by Dr. Satish S. Modi (April 25,
4:26-4:31 a.m.)
- A Prospective Randomized Comparison of Bilaterally Implanted
Extended Depth of Focus and Trifocal Intraocular Lenses, Presented
by Dr. Satish S. Modi (April 24, 11:06-11:11 a.m.)
- Prospective Analysis of PanOptix in Patients with Prior Myopic
Laser Vision Correction, Presented by Dr. Brett H. Mueller II
(April 25, 3:45-3:50 p.m.)‡
Additional educational opportunities and experiences for
surgeons
Visit the Alcon booth #1411 onsite during the meeting to learn
more about our surgical products and services. At the booth,
visitors will have the opportunity to experience the Alcon Fidelis™
Virtual Reality (VR) Ophthalmic Surgical Simulator—a portable VR
educational and training tool for cataract surgeons-in-training.
The SMART Educator IOL Vision Guide, which provides real-world
visual illustrations of Alcon IOLs will also be displayed. In
addition, Alcon will host a number of events, including:
- Surgeon Spotlight talks at the Alcon booth on Saturday and
Sunday (full schedule available on MyAlconatASCRS.com)
- Lunch symposium “Introducing the Clareon Collection of IOLs” on
Saturday from 11:30 a.m. to 1:00 p.m. at the Walter E. Washington
Convention Center, Salon GHI
- Afternoon symposium “Your MIGS Choice Matters” on Saturday from
5:00 to 6:30 p.m.
- Evening event “Making History Together: A Night of Innovation”
on Saturday from 7:00 to 9:00 p.m. at the National Museum of
American History
For information on Alcon events and news at ASCRS, please visit
MyAlconatASCRS.com.
About Clareon IOLs and Delivery
Systems
The family of Clareon intraocular lenses (IOLs) includes the
Clareon Aspheric Hydrophobic Acrylic and Clareon Aspheric Toric
IOLs, the Clareon PanOptix Trifocal Hydrophobic IOL, Clareon
PanOptix Toric, Clareon Vivity Extended Vision Hydrophobic
Posterior Chamber IOL and Clareon Vivity Toric IOLs. Each of these
IOLs is indicated for visual correction of aphakia in adult
patients following cataract surgery. In addition, the Clareon Toric
IOLs are indicated to correct pre-existing corneal astigmatism at
the time of cataract surgery. The Clareon PanOptix lens mitigates
the effects of presbyopia by providing improved intermediate and
near visual acuity while maintaining comparable distance visual
acuity with a reduced need for eyeglasses, compared to a monofocal
IOL. The Clareon Vivity lens mitigates the effects of presbyopia by
providing an extended depth of focus. Compared to an aspheric
monofocal IOL, the lens provides improved intermediate and near
visual acuity while maintaining comparable distance visual acuity.
All of these IOLs are intended for placement in the capsular bag.
Careful preoperative evaluation and sound clinical judgment should
be used by the surgeon to decide the risk/benefit ratio before
implanting any IOL in a patient with any of the conditions
described in the Directions for Use that accompany each IOL. Prior
to surgery, physicians should provide prospective patients with a
copy of the Patient Information Brochure available from Alcon,
informing them of possible risks and benefits associated with these
IOLs. Reference the Directions for Use labelling for each IOL for a
complete listing of indications, warnings and precautions.
About the AcrySof® IQ Vivity®
IOL
The non-diffractive AcrySof® IQ Vivity® Extended Vision
Posterior Chamber Intraocular Lens Model DFT015 (referred to as
AcrySof® IQ Vivity® IOL) is a UV-absorbing and blue light-filtering
foldable intraocular lens (IOL). This IOL, compared to a monofocal
IOL, provides an extended range of vision from distance to near
without increasing the incidence of visual disturbances.
Potential side effects: As with any surgery, there is an
implicit risk, whether or not the IOL is implanted. The
complications of the IOL implantation surgery ranges from minor
side effects (usually temporary) to serious complications. Patients
with previous illnesses or disorders (such as chronic infections of
the eye or eyelids or diabetes) may present a higher risk of
complications. Temporary surgical complications include, but are
not limited to, reactions to medications such as irritation or mild
allergic response, bleeding, redness, itching of the eye,
sensitivity to light, swelling, corneal edema (swelling of the
cornea), problems with the iris, cell growth in the IOL, and an
increase temporary eye pressure. There is a small risk of needing
further surgical treatment (such as IOL replacement implanted by a
different one or surgery to improve vision) after the implantation
of the initial IOL.
About the AcrySof® IQ PanOptix®
Trifocal Intraocular Lens (IOL)
The AcrySof IQ PanOptix Trifocal IOL is a type of multifocal IOL
used to focus images clearly onto the back of your eye (retina) to
allow clear vision after the cataract removal. In addition, the
center of the AcrySof IQ PanOptix Trifocal IOL allows for better
near (reading) vision and intermediate (computer work) vision
versus what a monofocal lens would provide.
Potential side effects: Due to the design of multifocal IOLs,
there are some side effects that can be associated with the AcrySof
IQ PanOptix Trifocal IOL models. These may be worse than with a
monofocal IOL, including visual disturbances, such as glare, rings
around lights, starbursts (rays around light sources), and reduced
contrast sensitivity (decrease in ability to distinguish objects
from their background, especially in dim lighting). These side
effects may make it more difficult to see while driving at night or
completing tasks in low lighting conditions such as at night or in
fog or in a dimly lit room after surgery as compared to before
surgery.
Further, a toric IOL corrects astigmatism only when it is placed
in the correct position in the eye. There is a possibility that the
toric IOL could be placed incorrectly or could move within the eye.
If the toric lens is not positioned correctly following surgery,
the change in your astigmatism correction by the IOL, along with
any necessary correction with glasses, may cause visual
distortions. If the lens rotates in your eye, you may need
additional surgery to reposition or replace the IOL.
About ARGOS® Biometer with Image
Guidance
ARGOS is a non-invasive, non-contact biometer based on Swept
Source Optical Coherence Tomography (SS-OCT). The device is
intended to acquire ocular measurements as well as perform
calculations to determine the appropriate intraocular lens (IOL)
power and type for implantation during intraocular lens placement.
Please refer to the ARGOS User Manual for a complete description of
proper use and maintenance, optical and technical specifications,
as well as a complete list of warnings and precautions.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye
care with a heritage spanning over 75 years, we offer the broadest
portfolio of products to enhance sight and improve people’s lives.
Our Surgical and Vision Care products touch the lives of more than
260 million people in over 140 countries each year living with
conditions like cataracts, glaucoma, retinal diseases and
refractive errors. Our more than 24,000 associates are enhancing
the quality of life through innovative products, partnerships with
Eye Care Professionals and programs that advance access to quality
eye care. Learn more at www.alcon.com.
* “Glistening-free” is defined as Modified
Miyata grade 0 or <25mv/mm2
** Alcon-sponsored study
† Based on year-over-year new equipment
install data. Data current as of Dec. 2020
‡ This study explores the use of PanOptix in
post-refractive patients. The safety and effectiveness of PanOptix
has not been established in patients with previous refractive
surgery. Careful preoperative evaluation and sound clinical
judgement should be used by the surgeon to decide the risk/benefit
ratio before implanting a lens in a patient with previous
refractive surgery.
References
- Nuijts, Rudy M., MD, PhD. Multinational Evaluation of a New
Aspheric Hydrophobic Monofocal Intraocular Lens 3 Years after
Implantation. ASCRS, Washington D.C. 23 April 2022.
- Multack, Sam., DO, ABO. Time Efficiency Metrics of an
Innovative Swept Source OCT Biometer (SS-OCT) for Cataract
Evaluation: A Comparative Time-and-Motion Study. ASCRS, Washington
D.C. 22 April 2022.
- Melendez, Robert F., MD, MBA, ABO. Comparison of toric
calculations from two swept-source optical coherence tomography
devices. ASCRS, Washington D.C. 22 April 2022.
- Blehm, Clayton G., MD, ABO. Refractive Outcomes Comparison of a
Swept-Source Optical Coherence Tomography Biometer and an Optical
Low Coherence Reflectometry Biometer. ASCRS, Washington D.C. 23
April 2022.
- Blehm, Clayton G., MD, ABO. Evaluation of Binocular Visual
Acuity and Refractive Stability in Novel Monofocal Hydrophobic
Intraocular Lens. ASCRS, Washington D.C., NV. 23 April 2022.
- Lapid-Gortzak, Ruth., MD, PhD. Real World Visual Performance
and Patient Satisfaction outcomes of novel shaping
Presbyopia-Correcting IOL in Cataract Patients. ASCRS, Washington
D.C. 25 April 2022.
- Zhu, Dagny., MD. Rate of Complete Spectacle Independence with a
Trifocal IOL: A Systematic Literature Review and Analysis. ASCRS,
Washington D.C., NV. 25 April 2022.
- AcrySof® IQ Vivity® Extended Vision IOL DFU. Alcon
Laboratories, Inc.; 2020.
- Kandavel, Rom., MD. Visual Outcomes and Patient Satisfaction of
the Vivity IOL Compared to Tecnis Monofocal IOL: a Final Data
Analysis and Biometric Correlations. ASCRS, Washington D.C. 25
April 2022.
- Scheepers, Marius A., BM BCh, MRCOphth, MM, FRCSC. Patient
Reported Quality of Vision of a Non-Diffractive Extended Vision IOL
and a Diffractive EDOF IOL after Bilateral Implantation. ASCRS,
Washington D.C. 25 April 2022.
Disclaimer
This press release contains “forward-looking statements” within
the meaning of the safe harbor provisions of the United States
Private Securities Litigation Reform Act of 1995. Forward-looking
statements can be identified by words such as: “anticipate,”
“intend,” “commitment,” “look forward,” “maintain,” “plan,” “goal,”
“seek,” “believe,” “project,” “estimate,” “expect,” “strategy,”
“future,” “likely,” “may,” “should,” “will” and similar references
to future periods.
Forward-looking statements are neither historical facts nor
assurances of future performance. Instead, they are based only on
our current beliefs, expectations and assumptions regarding the
future of our business, future plans and strategies, and other
future conditions. Because forward-looking statements relate to the
future, they are subject to inherent uncertainties and risks that
are difficult to predict. Some of these factors are discussed in
our filings with the United States Securities and Exchange
Commission, including our Form 20-F. Should one or more of these
uncertainties or risks materialize, or should underlying
assumptions prove incorrect, actual results may vary materially
from those anticipated. Therefore, you should not rely on any of
these forward-looking statements.
Forward-looking statements in this press release speak only as
of the date of its filing, and we assume no obligation to update
forward-looking statements as a result of new information, future
events or otherwise.
Connect with us on
Facebook
LinkedIn
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220419006006/en/
Media Relations Melanie
McCoy + 1 817 363 1247 + 1 682 304 8657 Melanie.McCoy@alcon.com
Alcon (NYSE:ALC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Alcon (NYSE:ALC)
Historical Stock Chart
From Sep 2023 to Sep 2024